Skip to main content
 
February 12, 2019

BERKELEY, CA – February 12, 2019 – Caribou Biosciences, Inc., a leading CRISPR genome editing company, announced today that it has expanded its Scientific Advisory Board (SAB) with the appointment of six new members: Emily Balskus, PhD; Ami Bhatt, MD, PhD; Dean Lee, MD, PhD; Jeffrey Rathmell, PhD; Noopur Raje, MD; and Cameron Turtle, MBBS, PhD. The newly appointed members will work with current SAB members and Caribou co-founders Jennifer Doudna, PhD and Martin Jinek, PhD.

December 12, 2018

BERKELEY, CA – December 12, 2018 – Caribou Biosciences, Inc., a leading genome editing company, announced today that it has appointed Natalie Sacks, MD to its Board of Directors. Dr. Sacks is an accomplished industry leader and oncology expert who has played a key role in the development and approval of several oncology therapeutics. 

September 10, 2018
The interference proceeding remains terminated without any determination of inventorship on CRISPR/Cas9 genome editing technology or its application to eukaryotic cells   University of California/University of Vienna/Dr. Charpentier have patent applications covering the use of CRISPR/Cas9 genome editing technology in all environments that do not interfere with the Broad’s patent claims in this proceeding  
June 19, 2018
Patent granted for groundbreaking work by Jennifer Doudna’s and Emmanuelle Charpentier’s research teams in CRISPR/Cas9 genome editing technology Patent covers use of optimized guide RNA molecules
May 3, 2018

BERKELEY, Calif.--(BUSINESS WIRE)--Caribou Biosciences, Inc., a leading genome editing company, announced today that it has appointed Timothy F. Herpin, Ph.D. as its first Chief Business Officer. In this role, Tim will lead the company's efforts in the areas of strategic partnerships, licensing agreements, and other value creation opportunities.

Pages